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of TLR7 (imiquimod) and/or 9 (CpG1826) ligands with DLI
resulted in powerful DLI-mediated GVL reactivity (P0.02),
without clinical signs of GVHD in established C3H.SW3B6
chimeras. The effect was mediated by DLI-derived anti-mHAg-
speciﬁc T cells since adoptive transfer of B6 DLI to the syngeneic
B63B6 chimeras in the presence of TLR ligands did not result in
antitumor immunity. To examine the effects of tissue damage,
established C3H.SW3B6.SJL chimeras were lethally re-irradi-
ated and received C3H.SW BM together with puriﬁed donor
CD8 T cells. Consistent with previous observation, these chime-
ras did not develop severe GVHD despite the fact that skin DCs
were predominantly host-derived. However, if TLR7 ligand was
administered prior to re-irradiation and administration of donor
CD8 T cells, all chimeras developed severe skin and systemic
GVHD (P0.01). To determine whether the donor CD8 T cells
directly recognize host mHAgs and induce tissue damage, we
constructed chimeras using as a host B62m-/- mice in which host
DCs and parenchyma are unable to present MHC class I-restricted
peptides. We found no clinical signs of skin or systemic GVHD in
the re-irradiated C3H.SW3B62m-/- chimeras that received pu-
riﬁed donor CD8 T cells after pre-treatment with TLR7 ligand.
Our data suggest that in MHC-matched setting (1) despite the
presence of host DCs the TLR-mediated signaling is critical for
induction of DLI-mediated GVL reactivity in established chime-
ras; (2) induction of GVHD in established chimeras requires not
only donor T cells, host APCs and TLR ligands, but also tissue
damage. These requirements for GVL reactivity and/or GVHD in
established MHC-matched chimeras clearly differ from those in
freshly irradiated MHC-matched or in established MHC-mis-
matched chimeras.
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SUCCESSFUL THERAPY OF STEROID-REFRACTORY ACUTE GRAFT-VER-
SUS HOST DISEASE WITH SEQUENTIAL ALEMTUZUMAB
Repp, R.1, Claviez, A.2, Schrauder, A.2, Schub, N.1, Gahn, B.1,
Gramatzki, M.1 1Division for Stem Cell Transplantation and Immu-
notherapy, 2nd Medical Department, University of Kiel, Kiel, Germany;
2Department of Pediatrics, University of Kiel, Kiel, Germany.
After allogeneic stem cell transplantation severe acute graft-
versus-host disease (GvHD) is the major limitation of this treat-
ment modality. While in acute GvHD addition of steroids to
immunosuppressive prophylaxis lead to a response rate of 30% to
70%, treatment options of steroid resistant acute GvHD are lim-
ited and no accepted standard for salvage therapy exists. Alemtu-
zumab (Campath-1H) is a commercially available humanized an-
tibody targeting the CD52 antigen, which is expressed on T-cells,
B-cells and on some monocyte derived dendritic cells. For years,
Alemtuzumab has been shown to be effective in GvHD prevention
when used in conditioning regimes, however infectious complica-
tions did limit this approach when routinely applied. In order to
evaluate efﬁcacy and safety of sequential alemtuzumab for severe
acute GvHD, ten patients with steroid-resistant acute GvHD of
grade III or IV involving the gut or/and liver were treated in our
Division. The initial three patients, all with advanced grade IV
GvHD of the liver and already receiving cyclosporine, mycophe-
nolate mofetil and high-dose steroids, were treated with up to 80
mg of alemtuzumab followed by additional 40 mg CD52 antibody
within the next four weeks. While dramatic clinical responses were
seen, such as a bilirubin level of 48 mg/dl returning to normal
within 6 weeks, virus reactivation and bacterial infections were
limiting this approach. Although pronounced lymphocyte deple-
tion seems inevitable for efﬁcacy, additional patients were treated
with lower doses of 20 to 30 mg Alemtuzumab, repeated approx-
imately every two weeks, while concomitant immunosuppressive
drugs could be tapered within 3 to 4 weeks. Acute GvHD improved
in all patients treated so far. A complete response of liver and gut
GvHD was seen in two patients, an additional patient developed a
vanishing bile duct syndrome but has no evidence of ongoing
GvHD. Another two patients are still on treatment with major
improvement of gut and liver-GVHD, respectively. Thus, alemtu-
zumab given sequentially in moderate doses shows promising ac-
tivity in severe, steroid refractory acute GvHD. However, moni-
toring for infectious complications, particularly by reactivated
viruses (CMV, adenovirus) is mandatory for months after treat-
ment.
322
IN VIVO BIOLUMINESCENCE AND [18F]-FHBG MICROPET IMAGING
STUDIES OF HUMAN T CELL TRAFFICKING, EXPANSION, AND XENO-
GENEIC GRAFT-VERSUS-HOST-DISEASE FOLLOWING DIFFERENT
ROUTES OF HUMAN T CELL ADMINISTRATION
Rettig, M.P.1, Nervi, B.1, Ritchey, J.K.1, Prior, J.L.1,
Piwnica-Worms, D.1, Wang, H.L.1, Bauer, G.1, Walker, J.1,
Bonyhadi, M.L.2, Berenson, R.J.2, Nolta, J.1, DiPersio, J.F.1 1Wash-
ington University School of Medicine, St. Louis, MO; 2Xcyte Therapies,
Inc., Seattle, WA.
GVHD is the major cause of morbidity and mortality following
allogeneic hematopoietic stem cell transplantation. We previously
demonstrated that 60% of sublethally irradiated NOD/SCID-
2mnull mice develop lethal xenogeneic GVHD (X-GVHD) fol-
lowing retroorbital (r.o.) injection of 107 human T cells (huT).
However, we observed no X-GVHD when the huT were admin-
istered through the lateral tail vein (i.v.). In the current studies, we
used in vivo bioluminescence imaging (BLI) and [18F]FHBG mi-
croPET to evaluate why the route of huT cell administration
affected huT cell engraftment and the development of lethal
XGVHD in NOD/SCID-2mnull mice. We generated huT that
co-expressed chimeric CD34-thymidine kinase (CD34-TK; for
[18F]FHBG microPET) and click beetle red luciferase-egfp
(CBRluc-egfp; for BLI) genes by transducing the cells with two
retroviral vectors, selecting for CD34, and sorting for EGFP
(huTTK/CBR). As before, sub-lethally irradiated NOD/SCID-
2mnull mice injected i.v. with 107 huTTK/CBR failed to develop
lethal XGVHD, whereas 60% of mice injected r.o. developed
lethal XGVHD. Serial whole body BLI and [18F]FHBG micro-
PET revealed very different trafﬁcking patterns and expansion
proﬁles between the i.v. and r.o. routes of huT cell administration.
HuTTK/CBR cells injected i.v. immediately trafﬁcked to the lungs
and failed to expand during the ﬁrst three weeks after infusion. In
contrast, a signiﬁcant portion of the r.o.-injected cells remained in
the retroorbital cavity and trafﬁcked to secondary lymphoid organs
during the ﬁrst 7 days after huTTK/CBR cell infusion. This altered
trafﬁcking of the r.o.-injected cells was associated with a 10-fold
and 5-fold increase in the huTTK/CBR BLI signal and [18F]FHBG
standardized uptake value, respectively, during the ﬁrst 2 weeks
after huT cell infusion, with the huTTK/CBR cells accumulating in
the skin, lymph nodes, lungs and gut. This homing pattern and
strong BLI and [18F]FHBG signals of the r.o.-injected huTTK/CBR
cells remained until death from GVHD. Importantly, histological
examination of the GVHD target tissues revealed changes consis-
tent with human GVHD. Therefore, this NOD/SCID-2mnull
mouse model provides a system to study the pathophysiology of
acute GVHD induced by human cells and aids in the development
of more effective therapies for human GVHD.
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DAY 30 POST-TRANSPLANT ABSOLUTE LYMPHOCYTE AND NATURAL
KILLER CELL COUNT STRONGLY PREDICT OUTCOME AFTER ALLOGE-
NEIC STEM CELL TRANSPLANTATION FOR HEMATOLOGICAL MALIG-
NANCY
Savani, B.N.1, Mielke, S.1, Rezvani, K.1, Yong, A.1, Shenoy, A.1,
Read, E.J.1, Hensel, N.1, Childs, R.1, Barrett, A.J.1 1Hematology
Branch, National Heart Lung and Blood Institute, National Institutes of
Health, Bethesda, MD.
One hundred and ﬁfty-seven patients with leukemia (80 CML,
48 AML, 29 ALL) received a T cell depleted myeloablative allo-
geneic stem cell transplant (SCT) (28 BM and 129 PB) from an
HLA-matched sibling between 09/1993-09/2005. Conditioning
consisted of TBI (12-13.6 Gy)  cyclophosphamide or combined
with ﬂudarabine. T cell dose ranged from 0.2 - 2  105CD3
cells/kg. GVHD prophylaxis was low dose cyclosporine (level 100-
200 ng/ml) in 103 and standard dose in 54. Patients without 
grade II acute GVHD received 1-2 donor lymphocyte infusions
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between days 45 and 100. Median age was 34 years (range 10-56);
78 had standard risk (SR) disease in ﬁrst remission or ﬁrst chronic
phase of CML, the remaining 79 had high risk (HR) disease. The
day 30 post-transplant lymphocyte count (LC30) was available in
154 patients and day 30 lymphocyte subset analysis was performed
in 54. Median LC30 was 400/	l, (range 10-3295) and 150/	l,
(range 6-1005) for CD56, CD16 CD3- NK cells (NK30).
Eighty-ﬁve patients (514%) survive (median 1392 days). Patients
with LC30 above median had signiﬁcantly (p0.002) faster neu-
trophil engraftment (18 vs.13 days), platelet engraftment (22 vs.18
days) and signiﬁcantly fewer febrile days before day30 pos-trans-
plantation (8.6 vs. 5). Patients with  median LC30 had signiﬁ-
cantly better transplant outcome: survival 71 vs. 36 p0.0001; DFS
71 vs. 31 %, p0.001; NRM 10 vs. 38, p0.001; relapse 22 vs. 51
%, p0.004;  II aGVHD 34 vs. 51 p0.05. In multivariate
analysis only disease risk and LC30 emerged as independent prog-
nostic factors: LC30 above 400/	l was associated with improved
survival (RR 4.3), DFS (RR 4.5), less relapse (RR 10.3), NRM (RR
3.3) and aGVHD (RR 2.3). LC30 impacted outcome of both HR
and SR disease groups. In the subset of 54 patients where NK cells
were quantitated LC30 and NK30 were highly correlated
(p0.001) and NK30 above 150/	l was also associated with im-
proved transplant outcome: In multivariate analysis, SR disease and
NK30 150/	l were the only independent factors associated with
better survival (RR 3), DFS (RR 3), less relapse (RR 4.8), less NRM
(RR 3) and less aGVHD (RR 5.3). This study did not deﬁne
whether LC30 is a surrogate for NK cell count or whether both are
a surrogate for another undetected prognostic factor. However the
inverse relationship between NK count and aGVHD raise the
possibility of an NK-mediated effect occurring via elimination of
host antigen presenting cells as described by others.
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TREATMENT OF STEROID-RESISTANT GRAFT-VERSUS-HOST DISEASE
WITH MONOCLONAL ANTIBODIES IN CHILDREN
Schechter, T.1, Afzal, S.1, Finkelstein, Y.1, Koren, G.1, Doyle, J.1,
Dupuis, L.L.1 1The Hospital for Sick Children, Toronto, ON, Canada.
Introduction: Acute graft-versus-host disease (aGVHD) carries
a major risk of morbidity and mortality in patients undergoing
hematopoietic stem cell transplantation (HSCT). The prognosis is
poor if aGVHD does not respond to corticosteroid treatment.
Recently, monoclonal antibodies such as daclizumab, a humanized
monoclonal IgG1, and inﬂiximab, a chimeric monoclonal antibody
that binds the precursor of tumor-necrosis factor-alfa, have shown
promising results in the treatment of corticosteroid-resistant
aGVHD. The reported complete response rate to monoclonal
antibody therapy in adults with aGVHD reaches as high as 47%.
Data describing the efﬁcacy of monoclonal antibodies in children
with corticosteroid-resistant aGVHD are limited.
Methods: We conducted a retrospective analysis to evaluate the
efﬁcacy of daclizumab and/or inﬂiximab in children diagnosed with
steroid-resistant aGVHD in the Hospital for Sick Children, To-
ronto, from July 2002 to December 2005. Corticosteroid-resistant
aGVHD was deﬁned as aGVHD which did not response or wors-
ened after a minimum of 5 days of corticosteroid therapy. Com-
plete response (CR) was deﬁned as full recovery without any signs
of aGVHD; partial response (PR) was deﬁned as improvement of
aGVHD symptoms in at least one organ without worsening in
other organs.
Results: Sixteen children were treated for aGVHD, twelve of
them had aGVHD grade 3 or 4. The organs involved were gut
(n6), skin (n4), liver (n2) and multi-organ involvement (n4).
Eleven children were given daclizumab; one was treated with
inﬂiximab and 4 with their combination. Fourteen children re-
ceived a full course of monoclonal antibodies for aGVHD. An
additional child died after the ﬁrst dose and one child developed
reactive arthritis attributed to daclizumab. Eight of the 14 children
who completed treatment (57%) responded: ﬁve had CR and three
had a PR. Three children developed fatal fungal infection and one
had fatal adenovirus infection during or shortly after monoclonal
antibody treatment. Eight children died: Seven from Transplant
Related Mortality (TRM) and 1 due to relapse. Median length of
follow up in the remaining 8 patients was 20 months.
Conclusion: Monoclonal antibodies were effective in the treat-
ment of children with corticosteroid-resistant acute GVHD. The
risk for infection, mainly fungal, was high.
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MUTANT INOSINE MONOPHOSPHATE DEHYDROGENASE II PROVIDES
SELECTIVE ADVANTAGE TO TRANSDUCED CELL LINES ABOVE WILD
TYPE
Schroeder, M.A.1, Rettig, M.P.1, Ritchey, J.K.1, DiPersio, J.F.1 1Wash-
ington University School of Medicine, Division of Oncology, Saint Louis,
MO.
Nonmyeloablative conditioning regimens followed by allogeneic
hematopoietic cell transplantation relies on pre and post transplan-
tation immunosuppression to overcome host-versus-graft reactions
and control graft-versus-host-disease (GVHD). Lower donor chi-
merism predicts for higher rejection and relapse (Blood 2004;
104(8):2254). Immunosuppression may inhibit the beneﬁcial graft-
versus-infection and graft-versus-leukemia effects. Genetically
modifying T cells with a drug resistance gene is one way to confer
protection from the effects of immunosuppressive agents, retain
donor T cell function, and increase donor T cell chimerism.
Mycophenolate mofetil (MMF) has been used in the post trans-
plant setting to decrease GVHD and reduce host vs. graft reac-
tions. MMF’s active metabolite is mycophenolic acid (MPA),
which inhibits the enzyme inosine monophosphate dehydrogenase
(IMPDH). Its type II isoform is the rate-limiting enzyme in de
novo guanosine synthesis and is preferentially expressed in acti-
vated T and B cells. A number of investigators have identiﬁed
IMPDH II mutants that have altered MPA binding capacity and
normal guanosine synthetic activity ex vivo. We have generated six
mutants of IMPDH II and retrovirally transduced them into 3 cell
lines: human T cells (Jurkat), canine large granular lymphocytes
(CLGL-90) and ﬁbroblasts (NIH3T3). The mutants include:
S276A, S276F, T333I  S351Y (IY), L30F  Q277R, Q277R 
A462T, and S276Y. We generated bicistronic (IRES containing)
retroviral vectors that expressed either HA-tagged wild type hu-
man IMPDH II (WT) or an HA-tagged IMPDH mutant and
EGFP. Forced expression of WT will increase the MPA IC50 3
fold (IC50  3uM) compared to non-transduced cells. Forced
expression of only the IY mutant in all cell lines tested was able to
transfer resistance to MPA in excess of WT (IC5050uM). To
show that resistance was related to the expression of the mutant
enzyme we correlated GFP by FACS with HA-IMPDH II expres-
sion by western blot analysis, and correlated this with resistance to
MPA in vitro. This is the ﬁrst report where forced expression only
of the IY mutant provides a clear enhanced resistance to MPA in
vitro compared to cells over expressing wild type IMPDH II.
Currently, we are generating bicistronic maloney based oncoret-
roviral vectors which carry a suicide gene (CD34-TK) and the IY
mutant which will allow us to pharmacologically modulate the level
of donor T cells after allogeneic stem cell transplantation.
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DONOR C3435T POLYMORPHISM IN THE MULTIDRUG RESISTANCE 1
(MDR1) GENE IS ASSOCIATED WITH THE INCIDENCE OF ACUTE AND
CHRONIC GRAFT-VERSUS-HOST DISEASE (GVHD) AFTER ALLOGENEIC
HEMATOPOIETIC STEM-CELL TRANSPLANTATION (ALLOSCT)
Shimoni, A.1, Ostrovsky, O.1, Galski, H.1, Hardan, I.1, Shem-Tov, N.1,
Yerushalmi, R.1, Nagler, A.1 1Chaim Sheba Medical Center, Tel-
Hashomer, Israel.
GVHD is the most signiﬁcant complication of alloSCT. HLA,
KIR and cytokine gene polymorphisms are involved in determin-
ing the risk of GVHD. The current study was designed to explore
the role of MDR1 gene polymorphism in predicting GVHD.
Single nucleotide polymorphisms at C3435T and G2677T were
determined in patients (pts) and donors using RFLP- based assay
and correlated with the occurrence GVHD. The study included
115 pts with various hematological malignancies after alloSCT
from related (n73) or unrelated (n42) donors. Fifty pts had
myeloablative and 65 had reduced-intensity conditioning. C3435T
polymorphism included CC, CT and TT genotypes that were
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